MapLight Therapeutics

MPLT · NASDAQ

$8.24+$0.24 (+3.00%)TodayMarket closed ·
Prev close $8.00

Latest news

  • Press releaseGlobe Newswire

    MapLight Therapeutics to Participate in Upcoming Investor Conference

  • Press releaseGlobe Newswire

    MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    MapLight Therapeutics Announces $150 Million Private Placement Financing

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • NewsVandana Singh

    MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

  • Press releaseBusiness Wire

    MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

  • Press releaseGlobe Newswire

    MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

  • Press releaseGlobe Newswire

    MapLight Therapeutics Announces Changes to Board of Directors

  • NewsVandana Singh

    MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents

  • News

    MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder

  • Press releaseGlobe Newswire

    MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

  • Press releaseGlobe Newswire

    MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    MapLight Therapeutics to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

  • NewsVandana Singh

    MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

  • News

    Earnings Scheduled For March 26, 2026

  • Press releaseGlobe Newswire

    MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    MapLight Therapeutics to Participate in Upcoming Investor Conferences

  • NewsAvi Kapoor

    Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday

  • NewsAvi Kapoor

    This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.